Sign in Subscribe
Class action lawsuits

Sarepta Therapeutics, Inc. Faces Securities Lawsuit Over Alleged Misconduct

Strategic Insights

— 1 min read

Allegations of securities fraud have been brought against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) in connection with the company's prescription gene therapy, ELEVIDYS. This lawsuit seeks to recover losses of shareholders who were allegedly misled by the company's false statements and concealment of significant safety risks associated with ELEVIDYS. The complaint specifically claims that defendants concealed adverse event data and failed to disclose severe side effects of ELEVIDYS treatment. This led to regulatory scrutiny and increased risk around the therapy's approvals.

Key Takeaways:

  • A class action securities lawsuit was filed against Sarepta Therapeutics, Inc. alleging securities fraud between June 22, 2023 and June 24, 2025.
  • The complaint alleges that defendants made false statements and/or concealed significant safety risks associated with ELEVIDYS, a prescription gene therapy for Duchenne.
  • The severity of adverse events from ELEVIDYS treatment allegedly caused the company to halt recruitment and dosing in ELEVIDYS trials, attracting regulatory scrutiny and increasing risk around the therapy's present and expanded approvals.
  • Sarepta stockholders who suffered losses during the relevant time period are being invited to join the lawsuit without any cost or obligation to participate.
  • Levi & Korsinsky LLP, a nationally-recognized securities litigation firm, is representing the shareholders in this case and has secured hundreds of millions of dollars for aggrieved investors in the past.
  • The firm has a track record of winning high-stakes cases and has extensive expertise representing investors in complex securities litigation.

Statistics:

  • Number of shareholders invited to join the lawsuit: not specified
  • Time period during which the alleged securities fraud occurred: June 22, 2023 and June 24, 2025
  • Percentage of investors allegedly misled by the company: not specified
  • Total amount recovered by Levi & Korsinsky for aggrieved shareholders: hundreds of millions of dollars
  • Number of employees serving clients at Levi & Korsinsky: over 70

Sources:

  • Newsfile Corp. press release (August 8, 2025)
  • Levi & Korsinsky LLP website (www.zlk.com)

Read more